Loading...

ETON ETON PHARMACEUTICALS INC Company Mergers 8-K Filing

TN P

TN

ETON PHARMACEUTICALS INC

(ETON)

2025 8-K

Show Summary

Show Summary

New Product Launches

Financial Statements

Asset Acquisitions

Product Expansion

Licensing Agreement

Financial Results

Positive Study Results

Increlex Acquisition

FDA Review Extension

Asset Acquisition

Asset Acquisition

Clinical Trial Results

Management Change

Licensing Agreement

Q3 Financial Results

Asset Acquisition

Financial Results Announcement

Shareholder Advisory Votes ...

Acceptance of NDA for hydro...

Accounting Firm Change

Annual Meeting of Stockholders

Financial Results Announcement

Submission of NDA for hydro...

Investments Cancelled

Acquisition Agreement

Financial Results Announcement

Financial Results Announcement

Acquisition of Drug Applica...

Earnings Report

Acquisition Agreement and A...

Annual Meeting Results

Earnings Reports

Earnings Reports

Regulation FD Disclosure

Appointment of Chief Busine...

FDA Accepts NDA Response fo...

External Links:

On March 31, 2025, Eton Pharmaceuticals out-licensed commercial rights to Increlex to Esteve Pharmaceuticals for $4 million upfront, with potential future rights for $6 million, while maintaining an expected annual revenue run rate of $80 million.

AI Assistant

ETON PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.